DOCSLIB.ORG

The Human Proteome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Vidal et al. Clinical Proteomics 2012, 9:6 http://www.clinicalproteomicsjournal.com/content/9/1/6 CLINICAL PROTEOMICS MEETING REPORT Open Access The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare Marc Vidal1, Daniel W Chan2, Mark Gerstein3, Matthias Mann4, Gilbert S Omenn5*, Danilo Tagle6, Salvatore Sechi7* and Workshop Participants Abstract A National Institutes of Health (NIH) workshop was convened in Bethesda, MD on September 26–27, 2011, with representative scientific leaders in the field of proteomics and its applications to clinical settings. The main purpose of this workshop was to articulate ways in which the biomedical research community can capitalize on recent technology advances and synergize with ongoing efforts to advance the field of human proteomics. This executive summary and the following full report describe the main discussions and outcomes of the workshop. Executive summary human proteome, including the antibody-based Human A National Institutes of Health (NIH) workshop was Protein Atlas, the NIH Common Fund Protein Capture convened in Bethesda, MD on September 26–27, 2011, Reagents, the mass spectrometry-based Peptide Atlas with representative scientific leaders in the field of pro- and Selected Reaction Monitoring (SRM) Atlas, and the teomics and its applications to clinical settings. The main Human Proteome Project organized by the Human purpose of this workshop was to articulate ways in which Proteome Organization. Several leading laboratories the biomedical research community can capitalize on re- have demonstrated that about 10,000 protein products, cent technology advances and synergize with ongoing of the about 20,000 protein-coding human genes, can efforts to advance the field of human proteomics. be identified and quantified in a single experimental Proteins are the major components of biological net- specimen; this figure may represent nearly the complete works and molecular machines, and proteins are the tar- complement of proteins actually expressed in a single gets for the large majority of drugs available today. cell type. In yeast the complete expressed proteome has Participants in this Workshop recognized that a deeper been identified. Even though a more comprehensive knowledge of the human proteome could help fill the characterization of the dynamic aspect of the proteome gap between genomes and phenotypes, transform the will require further technology development, it is a dis- way we develop diagnostics and therapeutics, and ruptive concept that almost all of the primary products thereby enhance overall biomedical research and future of the genome can be detected at the protein level in healthcare. The Human Genome Project and its many one single experiment. follow-on initiatives, including the HapMap and The Workshop was organized in five sessions: (1) pro- ENCODE, together with advances in protein sciences, tein networks; (2) integrating proteomics with other have provided a foundation for proteomic technologies omics; (3) quantitative proteomics by exploratory and and informatics resources. Several major initiatives are targeted methodologies; (4) study design and statistical already moving toward deep characterization of the challenges in clinical proteomics; and (5) proteomic technologies in a clinical setting. Sessions 1–3 consti- – * Correspondence: [email protected]; [email protected] tuted a main theme on systems biology; sessions 4 5 5University of Michigan, Ann Arbor, MI, USA represent a theme on strategies for clinical proteomics. 7 National Institute of Diabetes and Digestive and Kidney Diseases, The full agenda is at http://www3.niddk.nih.gov/fund/ National Institutes of Health, 6707 Democracy Blvd. Rm 611, Bethesda, MD 20892-5460, USA other/HumanProteome2011. This executive summary Full list of author information is available at the end of the article © 2012 Vidal et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Vidal et al. Clinical Proteomics 2012, 9:6 Page 2 of 11 http://www.clinicalproteomicsjournal.com/content/9/1/6 and the following full report describe the main discus- approximately 10,000 proteins from different genes in sions and outcomes of the workshop. human cell lines, for example. Such deep analyses per- mit direct comparison with deep sequencing of the Protein networks: toward a comprehensive wiring transcriptome, as well as with protein expression based diagram of human cells on immunohistochemistry, as documented in the The interactome network of cells is the complete set of Human Protein Atlas. macromolecular interactions that take place between genes and gene products; it is mostly mediated by pro- Study design and statistical challenges in clinical teins. Pull-down of diverse protein complexes and se- proteomics quencing of the components, plus other direct For the past decade, many of the individual institutes of measurements of protein-protein, protein-nucleic acid, the NIH have supported programs and projects to gen- and protein–lipids interactions now make it feasible to erate potential protein biomarkers for early or more create wiring diagrams for systems biology. The capabil- specific diagnosis or prognosis of a wide array of dis- ity of quantifying the main gene products and providing eases. There are many complex challenges in developing information on post-translational modifications and such omics-based tests. Heterogeneity of etiology, splice variants of proteins addresses the dynamic nature pathogenesis, and responses to therapy among patients of the networks. Experimental and natural perturbations with identical diagnoses, is common. Knowledge of of cultured cells and of whole organisms can then reveal mechanisms, mediated by pathways and networks, is connectivity and can test hypotheses of the blueprint fundamental to moving beyond statistical correlation as and dynamic regulation of phenotypes. Informatics tools a basis for biomarker development. Integration of data such as Cytoscape and databases such as BioGRID pro- across multiple levels of omics analyses should facilitate vide means of visualizing pathways, networks, and such knowledge development. Several general recom- interactomes. mendations for biomarker discovery projects were also made during the discussion. Participants emphasized Integrating proteomics with other omics the importance of specifying as early as possible in the Detailed integration of data and knowledge from mul- process the intended clinical use, and the importance of tiple omics technology platforms is essential for building proper study design in order to avoid introducing bias. and understanding the pathways from genome to pheno- Finally, it is important for translational scientists to types and the influence of environmental and behavioral understand the long path of discovery, confirmation, variables. The influence of allelic variants, splice variants, validation, clinical trials, and FDA approval to establish and post-translational modifications must be assessed in test validity and utility and gain reimbursement of the combined analyses of mRNA and protein abundance and laboratory service. response to perturbations. Single nucleotide polymorph- isms and alternative splicing can influence sites of post- translational modifications, magnifying their downstream Proteomic technologies in a clinical setting effects. Linking gene expression, protein expression, and The late-stage translation of proteomic technologies and metabolomics has become an attractive approach, facili- protein biomarker candidates into clinical tests requires tated by new bioinformatics tools. specification of the intended clinical use, sufficient evi- dence in preliminary studies to support the investment Quantitative proteomics by exploratory and targeted for a large-scale validation trial, demonstration of reliable mass spectrometry methods test performance characteristics, and sufficient clinical There has been stunning progress in mass spectrom- benefit to gain acceptance by the clinical community. It etry-based proteomics, with new technologies and com- is counterproductive to try to short-circuit these com- binations of instrumentation for bottom-up peptide plex steps, especially in the absence of a strong biological analysis, top-down protein analysis, and targeted quanti- foundation for the biomarker candidate or panel of bio- tative analysis of proteotypic peptides of selected pro- markers. The development of a roadmap for the transla- teins. The equipment and reagent sector for proteomics tion of proteomics technologies into clinical settings will is a major economic engine. These advances enable require close collaboration between researchers, indus- much more potent approaches for biomarker develop- tries, regulators, clinical chemists and clinicians, includ- ment and protein targeting with therapeutic agents. In ing private-public partnerships to leverage existing NIH contrast to recent studies limited to the most abundant programs. Such a partnership would accelerate the devel- dozens or hundreds of proteins in a biological speci- opment of clinically useful technologies and biomarkers men, current experiments are identifying, with a false and make a significant impact to fulfill the unmet clinical discovery
Recommended publications
  • Curriculum Vitae LINGJUN LI

    Curriculum Vitae LINGJUN LI

    Curriculum Vitae LINGJUN LI University of Wisconsin-Madison School of Pharmacy & Department of Chemistry 777 Highland Avenue Madison, WI 53705-2222 E-mail: [email protected] Phone : (608)265-8491 Fax : (608)262-5345 EDUCATION Ph.D. University of Illinois at Urbana-Champaign, 1995-2000 May 2000 Chemistry major (analytical and biomolecular) B.E. Beijing University of Technology, Beijing, China, 1987-1992 July 1992 Chemistry major (environmental analytical chemistry) EXPERTISE AND RESEARCH INTERESTS Bioanalytical chemistry, neurochemistry, biological mass spectrometry, neuropeptides, proteomics, peptidomics Research in my laboratory is focused on developing and implementing an array of novel mass spectrometry (MS) based methodologies to answer questions about the most complex and elusive set of signaling molecules, the neuropeptides, and gain new insights into the roles of peptide hormones and neurotransmitters play in the plasticity of neural circuits and behavior. Emphasis has been placed on constructing a multi-faceted and integrated platform that include high resolution in-situ peptide mapping, high sensitivity micro-separation techniques coupled with tandem MS de novo sequencing, isotopic labeling strategies, and new bioinformatics tools to allow large-scale discovery and functional analysis of novel neuropeptides. Furthermore, both mass spectrometric imaging technologies and in vivo microdialysis sampling tools have been implemented to follow neuropeptide distribution and secretion in unprecedented details. Towards the goal of
  • Cancer Informatics: New Tools for a Data-Driven Age in Cancer Research Warren Kibbe1, Juli Klemm1, and John Quackenbush2

    Cancer Informatics: New Tools for a Data-Driven Age in Cancer Research Warren Kibbe1, Juli Klemm1, and John Quackenbush2

    Cancer Focus on Computer Resources Research Cancer Informatics: New Tools for a Data-Driven Age in Cancer Research Warren Kibbe1, Juli Klemm1, and John Quackenbush2 Cancer is a remarkably adaptable and formidable foe. Cancer Precision Medicine Initiative highlighted the importance of data- exploits many biological mechanisms to confuse and subvert driven cancer research, translational research, and its application normal physiologic and cellular processes, to adapt to thera- to decision making in cancer treatment (https://www.cancer.gov/ pies, and to evade the immune system. Decades of research and research/key-initiatives/precision-medicine). And the National significant national and international investments in cancer Strategic Computing Initiative highlighted the importance of research have dramatically increased our knowledge of the computing as a national competitive asset and included a focus disease, leading to improvements in cancer diagnosis, treat- on applying computing in biomedical research. Articles in the ment, and management, resulting in improved outcomes for mainstream media, such as that by Siddhartha Mukherjee in many patients. the New Yorker in April of 2017 (http://www.newyorker.com/ In melanoma, the V600E mutation in the BRAF gene is now magazine/2017/04/03/ai-versus-md), have emphasized the targetable by a specific therapy. BRAF is a serine/threonine protein growing importance of computing, machine learning, and data kinase activating the MAP kinase (MAPK)/ERK signaling pathway, in biomedicine. and both BRAF and MEK inhibitors, such as vemurafenib and The NCI (Rockville, MD) recognized the need to invest in dabrafenib, have shown dramatic responses in patients carrying informatics. In 2011, it established a funding opportunity, the mutation.
  • Finding New Order in Biological Functions from the Network Structure of Gene Annotations

    Finding New Order in Biological Functions from the Network Structure of Gene Annotations

    Finding New Order in Biological Functions from the Network Structure of Gene Annotations Kimberly Glass 1;2;3∗, and Michelle Girvan 3;4;5 1Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA 2Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA 3Physics Department, University of Maryland, College Park, MD, USA 4Institute for Physical Science and Technology, University of Maryland, College Park, MD, USA 5Santa Fe Institute, Santa Fe, NM, USA The Gene Ontology (GO) provides biologists with a controlled terminology that describes how genes are associated with functions and how functional terms are related to each other. These term-term relationships encode how scientists conceive the organization of biological functions, and they take the form of a directed acyclic graph (DAG). Here, we propose that the network structure of gene-term annotations made using GO can be employed to establish an alternate natural way to group the functional terms which is different from the hierarchical structure established in the GO DAG. Instead of relying on an externally defined organization for biological functions, our method connects biological functions together if they are performed by the same genes, as indicated in a compendium of gene annotation data from numerous different experiments. We show that grouping terms by this alternate scheme is distinct from term relationships defined in the ontological structure and provides a new framework with which to describe and predict the functions of experimentally identified sets of genes. Tools and supplemental material related to this work can be found online at http://www.networks.umd.edu.
  • 2Nd ANNUAL NORTH AMERICAN MASS SPECTROMETRY SUMMER SCHOOL

    2Nd ANNUAL NORTH AMERICAN MASS SPECTROMETRY SUMMER SCHOOL

    2nd ANNUAL NORTH AMERICAN MASS SPECTROMETRY SUMMER SCHOOL JULY 21-24, 2019 | MADISON, WISCONSIN Parabola of Neon (1913) Featured on the cover is an early 20th century parabola mass spectrograph. The early mass spectrometers, pioneered by J. J. Thomson, used electric and magnetic fields to disperse ion populations on photographic plates. Depending on their masses, the ions were dispersed along parabolic lines with those of the highest energy landing in the center and those with the least extending to the outermost edges. Positive ions are imaged on the upper half of the parabola while negative ions are deflected to the bottom half. Note that Ne produces two lines in the spectrum. Francis Aston, a former Thomson student, concluded from these data that stable elements also must have isotopes. These observations won Aston the Nobel Prize in Chemistry in 1922. Grayson, M.A. Measuring Mass: From Positive Rays to Proteins. 2002. Chemical Heritage Press, Philadelphia. Welcome to the 2nd Annual North American Mass Spectrometry Summer School We are proud to assemble world-leading experts in mass spectrometry for this second annual mass spectrometry summer school. We aim for you to experience an engaging and inspiring program covering the fundamentals of mass spectrometry and how to apply this tool to study biology. Also infused in the course are several workshops aimed to promote professional development. We encourage you to actively engage in discussion during all lectures, workshops, and events. This summer school is made possible through generous funding from the National Science Foundation (Plant Genome Research Program, Grant No. 1546742), the National Institutes of Health National Center for Quantitative Biology of Complex Systems (P41 GM108538), and the Morgridge Institute for Research.
  • Extracting Biological Meaning from High-Dimensional Datasets John

    Extracting Biological Meaning from High-Dimensional Datasets John

    Extracting Biological Meaning from High-Dimensional Datasets John Quackenbush Dana-Farber Cancer Institute and the Harvard School of Public Health, U.S.A. The revolution of genomics has come not from the ”completed” genome sequences of hu- man, mouse, rat, and other species. Nor has it come from the preliminary catalogues of genes that have been produced in these species. Rather, the genomic revolution has been in the creation of technologies - transcriptomics, proteomics, metabolomics - that allow us to rapidly assemble data on large numbers of samples that provide information on the state of tens of thousands of biological entities. Although the gene-by-gene hypothesis testing approach remains the standard for dissecting biological function, ’omic technolo- gies have become a standard laboratory tool for generating new, testable hypotheses. The challenge is now no longer generating the data, but rather in analyzing and inter- preting it. Although new statistical and data mining techniques are being developed, they continue to wrestle with the problem of having far fewer samples than necessary to constrain the analysis. One way to deal with this problem is to use the existing body of biological data, including genotype, phenotype, the genome, its annotation and the vast body of biological literature. Through examples, we will demonstrate show how diverse datasets can be used in conjunction with computational tools to constrain ’omics datasets and extract meaningful results that reveal new features of the underlying biology. [ John Quackenbush, 44 Binney Street, SM822 Boston, MA 02115-6084, U.S.A.; [email protected]].
  • University of California, San Diego

    University of California, San Diego

    UC San Diego UC San Diego Electronic Theses and Dissertations Title Novel proteomics methods for increased sensitivity, greater proteome coverage, and global profiling of endogenous SUMO modification sites Permalink https://escholarship.org/uc/item/4xq3v9wd Author Meyer, Jesse Gerard Publication Date 2015 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Novel proteomics methods for increased sensitivity, greater proteome coverage, and global profiling of endogenous SUMO modification sites A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Chemistry by Jesse Gerard Meyer Committee in charge: Professor Elizabeth A. Komives, Chair Professor Nuno Bandeira, Co-Chair Professor Jack Dixon Professor Randy Hampton Professor Judy Kim Professor Wei Wang 2015 Copyright Jesse Gerard Meyer, 2015 All rights reserved The dissertation of Jesse Gerard Meyer is approved, and it is acceptable in quality and form for publication on microfilm: Co-Chair Chair University of California, San Diego 2015 iii DEDICATION I dedicate this work to my family and friends. iv TABLE OF CONTENTS Signature Page…….……..………………………………………………………… iii Dedication……………………………………………………..…………………… iv Table of Contents………………………………………………………………... …v List of Abbreviations ……………………………………………………………… xi Lists of Figures……………………………………………….………….………… xiv Lists of Tables…………………………………………………...…….…………… xvii Acknowledgements…………………………………………………………………
  • Molecular Processes During Fat Cell Development Revealed by Gene

    Molecular Processes During Fat Cell Development Revealed by Gene

    Open Access Research2005HackletVolume al. 6, Issue 13, Article R108 Molecular processes during fat cell development revealed by gene comment expression profiling and functional annotation Hubert Hackl¤*, Thomas Rainer Burkard¤*†, Alexander Sturn*, Renee Rubio‡, Alexander Schleiffer†, Sun Tian†, John Quackenbush‡, Frank Eisenhaber† and Zlatko Trajanoski* * Addresses: Institute for Genomics and Bioinformatics and Christian Doppler Laboratory for Genomics and Bioinformatics, Graz University of reviews Technology, Petersgasse 14, 8010 Graz, Austria. †Research Institute of Molecular Pathology, Dr Bohr-Gasse 7, 1030 Vienna, Austria. ‡Dana- Farber Cancer Institute, Department of Biostatistics and Computational Biology, 44 Binney Street, Boston, MA 02115. ¤ These authors contributed equally to this work. Correspondence: Zlatko Trajanoski. E-mail: [email protected] Published: 19 December 2005 Received: 21 July 2005 reports Revised: 23 August 2005 Genome Biology 2005, 6:R108 (doi:10.1186/gb-2005-6-13-r108) Accepted: 8 November 2005 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2005/6/13/R108 © 2005 Hackl et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which deposited research permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Gene-expression<p>In-depthadipocytecell development.</p> cells bioinformatics were during combined fat-cell analyses with development de of novo expressed functional sequence annotation tags fo andund mapping to be differentially onto known expres pathwayssed during to generate differentiation a molecular of 3 atlasT3-L1 of pre- fat- Abstract Background: Large-scale transcription profiling of cell models and model organisms can identify novel molecular components involved in fat cell development.
  • Day 1 Session 4

    Day 1 Session 4

    USING NETWORKS TO RE-EXAMINE THE GENOME-PHENOME CONNECTION John Quackenbush Dana-Farber Cancer Institute Harvard School of Public Health The WØRD When you feel it in your gut, you know it must be right. 697 SNPs explain 20% of height ~2,000 SNPs explain 21% of height ~3,700 SNPs explain 24% of height ~9,500 SNPs explain 29% of height 97 SNPs explain 2.7% of BMI All common SNPs may explain 20% of BMI Do we give up on GWAS, fine map everything, or think differently? eQTL Analysis Use genome-wide data on genetic variants (SNPs = Single Nucleotide Polymorphisms) and gene expression data together Treat gene expression as a quantitative trait Ask, “Which SNPs are correlated with the degree of gene expression?” Most people concentrate on cis-acting SNPs What about trans-acting SNPs? John Platig eQTL Networks: A simple idea • eQTLs should group into communities with core SNPs regulating particular cellular functions • Perform a “standard eQTL” analysis using Matrix_EQTL: Y = β0 + β1 ADD + ε where Y is the quantitative trait and ADD is the allele dosage of a genotype. John Platig Which SNPs affect function? Many strong eQTLs are found near the target gene. But what about multiple SNPs that are correlated with multiple genes? SNPs Can a network of SNP- gene associations inform the functional roles of these SNPs? Genes John Platig Results: COPD John Platig What about GWAS SNPs? John Platig What about GWAS SNPs? The “hubs” are a GWAS desert! John Platig What are the critical areas? Abraham Wald: Put the armor where the bullets aren’t! http://cameronmoll.com/Good_vs_Great.pdf Network Structure Matters? • Are “disease” SNPs skewed towards the top of my SNP list as ranked by the overall out degree? • No! • The collection of highest-degree SNPs is devoid of disease-related SNPs • Highly deleterious SNPs that affect many processes are probably removed by strong negative selection.
  • Roles of the Mathematical Sciences in Bioinformatics Education

    Roles of the Mathematical Sciences in Bioinformatics Education

    Roles of the Mathematical Sciences in Bioinformatics Education Curtis Huttenhower 09-09-14 Harvard School of Public Health Department of Biostatistics U. Oregon Who am I, and why am I here? • Assoc. Prof. of Computational Biology in Biostatistics dept. at Harvard Sch. of Public Health – Ph.D. in Computer Science – B.S. in CS, Math, and Chemistry • My teaching focuses on graduate level: – Survey courses in bioinformatics for biologists – Applied training in systems for research computing – Reproducibility and best practices for “computational experiments” 2 HSPH BIO508: Genomic Data Manipulation http://huttenhower.sph.harvard.edu/bio508 3 Teaching quantitative methods to biologists: challenges • Biologists aren’t interested in stats as taught to biostatisticians – And they’re right! – Biostatisticians don’t usually like biology, either – Two ramifications: excitement gap and pedagogy • Differences in research culture matter – Hands-on vs. coursework – Lab groups – Rotations – Length of Ph.D. –… • There are few/no textbooks that are comprehensive, recent, and audience-appropriate – Choose any two of three 4 Teaching quantitative methods to biologists: (some of the) solutions • Teach intuitions – Biologists will never need to prove anything about a t-distribution – They will benefit minimally from looking up when to use a t-test – They will benefit a lot from seeing when a t-test lies (or doesn’t) • Teach applications – Problems/projects must be interactive – IPython Notebook / RStudio / etc. are invaluable • Teach writing • Demonstrate
  • Expert Panel Report of the Cancer Systems Biology Consortium Program Evaluation

    Expert Panel Report of the Cancer Systems Biology Consortium Program Evaluation

    MEMORANDUM November 11, 2020 To: Hannah Dueck National Cancer Institute (NCI) From: Carly S. Cox Science and Technology Policy Institute (STPI) Through: Bill Brykczynski Acting Director, STPI CC: Amana Abdurrezak and Brian Zuckerman STPI Subject: Expert Panel Report of the Cancer Systems Biology Consortium Program Evaluation The National Cancer Institute (NCI) Division of Cancer Biology (DCB) asked the Science and Technology Policy Institute (STPI) to facilitate an expert panel to evaluate the Cancer Systems Biolgoy Consortium (CSBC) ahead of its 2020 renewal request. To fulfill this request, STPI selected panelists, issued invitations, convened the panel for meetings to discuss program evaluation materials, facilitated a meeting between CSBC investigators and panelists, and supported the panel in its deliberations. Based on the NCI provided program information, conversations with CSBC resources, and information gathered at the CSBC Annual Meeting, the panel formulated answers to the five program evaluation questions charged to them by NCI. STPI summarized the panel’s answers to these questions in a draft document and completed a round of revisions with the panel and NCI. A finalized summary of the panel’s response to the program evaluation questions is provided in the attached document. ReleasedAttachment: “Expert Panel Report of the CancerMarch Systems Biology Consortium 2021 Program Evaluation” 1 Expert Panel Report of the Cancer Systems Biology Consortium Program Evaluation Edison Liu, Chair The Jackson Laboratories Kenneth Buetow Arizona State University Teresa Przytycka NIH National Center for Biotechnology Information John Quackenbush Harvard T.H. Chan School of Public Health Cynthia Reinhart-King Vanderbilt University October 2020 This document is under review and is subject to modification or withdrawal.
  • Top-Down Proteomics: Applications, Recent Developments and Perspectives

    Top-Down Proteomics: Applications, Recent Developments and Perspectives

    JOURNAL OF APPLIED BIOANALYSIS, Apr. 2016, p. 52-75. http://dx.doi.org/10.17145/jab.16.009 Vol. 2, No. 2 REVIEW Top-down proteomics: applications, recent developments and perspectives Annapurna Pamreddy1, Nagender Reddy Panyala2,* 1Department of chemistry, Masaryk University, Brno, Czech Republic, 2Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA (Received: 30 December 2015, Revised 22 March 2016, Accepted 4 April 2016 ) Now-a-days, top-down proteomics (TDP) is a booming approach for the analysis of intact pro- teins and it is attaining significant interest in the field of protein biology. The term has emerged as an alternative to the well-established, bottom-up strategies for analysis of peptide fragments de- rived from either enzymatically or chemically digestion of intact proteins. TDP is applied to mass spectrometric analysis of intact large biomolecules that are constituents of protein complexes and assemblies. This article delivers an overview of the methodologies in top-down mass spec- trometry, mass spectrometry instrumentation and an extensive review of applications covering the venomics, biomedical research, protein biology including the analysis of protein post-transla- tional modifications (PTMs), protein biophysics, and protein complexes. In addition, limitations of top-down proteomics, challenges and future directions of TDP are also discussed. Keywords: Top-down, protein biology, mass spectrometry, fragmentation techniques, data analysis. Introduction specificity at the expense of far higher experimental re- In recent years the mass spectrometry (MS) ionization quirements by directly introducing the proteins into the techniques such as ESI [1] and MALDI [2] have been mass spectrometer. The top-down method is being de- applied for the detection of a wide variety of large bio- veloped progressively in specific applications, with 18% polymers, such as proteins [3,4], lipids, and nucleic ac- of proteomics papers/posters at the 2007 meetings of ids.
  • Abstract Book

    Abstract Book

    ABSTRACT BOOK 16th ANNUAL US HUPO Conference Novel Proteomic Perspectives on Aging, Cancer and Disease March 8–11, 2020 The Westin Seattle, Seattle Washington, USA 16th Annual US HUPO Conference The Co-chairs would like to express their sincere gratitude to the following sponsors for their generous financial support: PLATINUM SPONSORS ADDITIONAL SUPPORT *Funding for this conference was made possible (in part) by 1R13CA250291-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Bruker at US HUPO timsTOF Pro and PASEF The New Standard for Shotgun Proteomics timsTOF Pro with PASEF technology delivers revolutionary improvements in scan speed, coupled with enhanced specificity and high sensitivity. Near 100% duty cycle using dual TIMS technology Unrivalled MS/MS speed >100Hz Discover more proteins using PASEF Meet the Experts Booth #204 Bruker Lunch Seminar Monday, March 9th, 12:15pm – 1:30pm; Cascade Room #2 diaPASEF: combining improved ion usage efficiency with data independent acquisition to quantify proteomes Dr. Ben Collins, Reader in the School of Biological Sciences at Queen’s University Belfast Building protein interaction networks to understand KRAS lung cancer Dr. Peter Jackson, Professor, Stanford University School of Medicine Register here